A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

ClinicalTrials.gov ID: NCT07081646

Public ClinicalTrials.gov record NCT07081646. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 12:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.

Study identification

NCT ID: NCT07081646
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Enrollment: 91 participants

Conditions and interventions

Conditions

Interventions

AZD0120 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 17, 2025
Primary completion: Aug 14, 2029
Completion: Feb 13, 2031
Last update posted: Mar 23, 2026

2025 – 2031

United States locations

U.S. sites: 12
U.S. states: 10
U.S. cities: 10

Facility	City	State	ZIP	Site status
Research Site	Phoenix	Arizona	85028	Recruiting
Research Site	San Francisco	California	94143	Not yet recruiting
Research Site	Tampa	Florida	33612	Recruiting
Research Site	Boston	Massachusetts	02215	Recruiting
Research Site	Detroit	Michigan	48201	Recruiting
Research Site	Rochester	Minnesota	55905	Recruiting
Research Site	St Louis	Missouri	63110	Recruiting
Research Site	New York	New York	10016	Recruiting
Research Site	New York	New York	10032	Recruiting
Research Site	New York	New York	10065	Recruiting
Research Site	Cleveland	Ohio	44195	Recruiting
Research Site	Nashville	Tennessee	37232	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07081646, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 23, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07081646 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →